NantKwest

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares soar after the clinical-stage biotech releases exciting news.

Why NantKwest Stock Is Skyrocketing Today

NantKwest: The Market Finally Recognizes The Opportunity

NantKwest has recently reported positive results and progress in its NK cell pipeline programs, but the shares have continued to sell off.

NantKwest: Continues To Sell Off Despite The Clinical Progress

NantKwest was a highly anticipated IPO that only took a couple of years to be "busted" Although the stock might be busted, the company is still making headway.

NantKwest: Still Going For A Cancer Moonshot

As of late, it has definitely been a great time to be an investor in NantKwest.

Will NantKwest Continue to Surge Higher?

News for NantKwest Stock (NK)